Starpharma Holdings (ASX:SPL) OCF Margin %: 36.11% (As of Dec. 2025)

What is Starpharma Holdings OCF Margin %?

Starpharma Holdings ASX:SPL +0.72% 52 OCF Margin % is 36.11% as of Dec. 2025. GuruFocus rates ASX:SPL with a GF Score™ of 52/100 and a GF Value™ of A$0.43 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 959 Biotechnology companies, Starpharma Holdings ranks better than 64.44% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Starpharma Holdings's Cash Flow from Operations for the six months ended in Dec. 2025 was A$3.91 Mil. Starpharma Holdings's Revenue for the six months ended in Dec. 2025 was A$10.83 Mil. Therefore, Starpharma Holdings's OCF Margin % for the quarter that ended in Dec. 2025 was 36.11%.

As of today, Starpharma Holdings's current OCF Yield % is -0.29%.

The historical rank and industry rank for Starpharma Holdings's OCF Margin % or its related term are showing as below:

ASX:SPL' s OCF Margin % Range Over the Past 10 Years
Min: -823.58 Med: -370.79 Max: -84.17
Current: -6.15

During the past 13 years, the highest OCF Margin % of Starpharma Holdings was -84.17%. The lowest was -823.58%. And the median was -370.79%.

ASX:SPL's OCF Margin % is ranked better than
64.44% of 959 companies
in the Biotechnology industry
Industry Median: -66.52 vs ASX:SPL: -6.15

Starpharma Holdings OCF Margin % Related Terms

Starpharma Holdings OCF Margin % Historical Data

* Premium members only.

The historical data trend for Starpharma Holdings's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Starpharma Holdings OCF Margin % Chart

Starpharma Holdings Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

OCF Margin %

Get a 7-Day Free Trial

-823.58

-281.12

-460.46

-84.17

-137.60

Starpharma Holdings Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
OCF Margin %	Get a 7-Day Free Trial															29.15	-831.04	-105.72	-157.51	36.11

ASX:SPL vs VRTX, REGN, ALNY: OCF Margin % Comparison

For the Biotechnology subindustry, Starpharma Holdings's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Starpharma Holdings OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Starpharma Holdings's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Starpharma Holdings's OCF Margin % falls into.

Save Embed

52GF Score

Starpharma Holdings Ltd ASX:SPL

OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Starpharma Holdings OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Starpharma Holdings's OCF Margin for the fiscal year that ended in Jun. 2025 is calculated as

OCF Margin	=	Cash Flow from Operations (A: Jun. 2025 )	/	Revenue (A: Jun. 2025 )
	=	-6.759	/	4.912
	=	-137.60 %

Starpharma Holdings's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin	=	Cash Flow from Operations (Q: Dec. 2025 )	/	Revenue (Q: Dec. 2025 )
	=	3.911	/	10.832
	=	36.11 %

Frequently Asked Questions Learn more about OCF Margin % →

What does a OCF Margin % of 36.11% mean?

Starpharma Holdings (ASX:SPL) has a OCF Margin % of 36.11% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Starpharma Holdings and its competitors. According to the industry distribution chart, Starpharma Holdings ranks #341 out of 959 companies in the Biotechnology industry, placing it in the top 35.6%.

Is Starpharma Holdings' OCF Margin % too high?

Starpharma Holdings' current OCF Margin % is 36.11%. Based on the distribution chart, Starpharma Holdings ranks #341 out of 959 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Starpharma Holdings has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Starpharma Holdings' OCF Margin % compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, Starpharma Holdings ranks #341 out of 959 companies for OCF Margin %. This puts Starpharma Holdings in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good OCF Margin % for a Biotechnology company?

A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high OCF Margin % mean?

A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Starpharma Holdings and its competitors. Starpharma Holdings's current OCF Margin % is 36.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Starpharma Holdings stock overvalued right now?

Based on GuruFocus' analysis, Starpharma Holdings (ASX:SPL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.43, compared to a current price of A$0.70 — trading 61.6% above its estimated fair value. The current OCF Margin % is 36.11%. Starpharma Holdings' overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is OCF Margin % calculated?

OCF Margin % is calculated from a company's financial statements. For Starpharma Holdings (ASX:SPL), the current OCF Margin % is 36.11% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Starpharma Holdings (ASX:SPL) Overvalued in 2026?

Based on GuruFocus' analysis, Starpharma Holdings stock appears to be overvalued. The current stock price of A$0.70 is trading 61.6% above its estimated GF Value™ of A$0.43. GuruFocus considers Starpharma Holdings to be Significantly Overvalued.

Key valuation signals for ASX:SPL:

OCF Margin %: 36.11%
GF Value™: A$0.43 vs. price of A$0.70 (61.6% above fair value)
GF Score™: 52/100 with 3 warning signs

No single metric tells the full story. See the ASX:SPL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Starpharma Holdings Business Description

Industry Healthcare Biotechnology

Comparable Companies ASX:TTX ASX:OCC ASX:RCE ASX:ACW ASX:CUV ASX:RAC ASX:NYR ASX:ILA ASX:DXB ASX:ATH VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges SPHRY:USA SPHRF:USA PQ6:Germany

Address 4-6 Southampton Crescent, Abbotsford, Melbourne, VIC, AUS, 3067

Website https://www.starpharma.com

Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating, and VIRALEZE, an antiviral nasal spray.

52GF Score

Get the complete analysis for ASX:SPL

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.70

Price

A$0.43

GF Value

View ASX:SPL Analysis

See OCF Margin % data for all stocks →